The Arab Drug Company Cash Flow Statement

Financials in millions EGP. Fiscal year is July - June.

Millions EGP. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	256.4	227.86	102.82	82.77	76.3	101.41
Depreciation & Amortization	25,379	25,361	3.37	3.26	9.39	7.81
Other Operating Activities	-25,412	-25,424	29.58	1.48	-52.82	-72.65
Operating Cash Flow	223.31	164.28	135.77	87.51	32.87	36.58
Operating Cash Flow Growth	79.86%	21.00%	55.15%	166.22%	-10.14%	-50.05%
Capital Expenditures	-133.18	-198.9	-285.98	-63.18	-89.92	-28.87
Investment in Securities	-	-	-	-	13.88	-
Other Investing Activities	8.47	19.27	27.92	1.07	1.63	4.34
Investing Cash Flow	-124.71	-179.63	-258.07	-62.11	-74.41	-24.53
Short-Term Debt Issued	-	-	-	-	27.33	-
Long-Term Debt Issued	-	35.79	339.09	51.3	52.54	-
Total Debt Issued	46.7	35.79	339.09	51.3	79.87	-
Long-Term Debt Repaid	-	-97.24	-44.55	-	-	-
Total Debt Repaid	-89.26	-97.24	-44.55	-	-	-
Net Debt Issued (Repaid)	-42.56	-61.46	294.54	51.3	79.87	-
Common Dividends Paid	-82.53	-63.11	-36.1	-37.49	-43.54	-38.85
Other Financing Activities	-57.03	-48.56	-23.09	-1.68	-0.95	-
Financing Cash Flow	-182.12	-173.12	235.35	12.13	35.38	-38.85
Miscellaneous Cash Flow Adjustments	71.1	35.04	69.18	-27.33	-	-0
Net Cash Flow	-12.42	-153.44	182.24	10.2	-6.15	-26.8
Free Cash Flow	90.13	-34.63	-150.22	24.33	-57.04	7.71
Free Cash Flow Growth	-	-	-	-	-	-89.09%
Free Cash Flow Margin	7.31%	-3.10%	-19.12%	3.84%	-11.29%	1.44%
Free Cash Flow Per Share	7.51	-2.89	-12.52	2.03	-4.21	0.56
Cash Interest Paid	57.03	48.56	23.09	1.68	0.95	-
Cash Income Tax Paid	61.15	47.18	34.73	35.09	51.95	52.97
Levered Free Cash Flow	25,351	25,184	-184.62	-24.95	-121.56	-1.96
Unlevered Free Cash Flow	25,387	25,214	-170.19	-23.5	-120.96	-1.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.